We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Novartis Purchase Of Chiron Puts Spotlight On Biologics

Law360 (November 1, 2005, 12:00 AM EST) -- Drug maker Novartis AG’s acquisition of Chiron Corp. will expand the Swiss company’s footprints in the U.S. biotech market even as its generics division braces for a battle to launch the first generic biotech drugs in the United States.

Chiron Corp. said Monday its board of directors has accepted a $5.1 billion takeover offer from Novartis, which already owns 42% of the beleaguered biotech company. Founded in 1981, Chiron is the third-oldest biotechnology company after industry leaders Amgen Inc. and Genentech Inc.

The acquisition will give...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.